文献速递炎症性肠病

布罗达鲁单抗治疗中重度克罗恩病的随机双盲安慰剂对照2期研究

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
PubMed 文献 · Am J Gastroenterol · 2016-08-02

这项2期随机双盲安慰剂对照剂量探索研究评估布罗达鲁单抗(抗白介素-17受体单克隆抗体)治疗中重度活动性克罗恩病的安全性和疗效。因活动治疗组克罗恩病恶化病例失衡而提前终止,共随机130例。第6周各剂量组缓解率与安慰剂组相近,未见有意义的疗效。

要点

  • 研究因活动治疗组克罗恩病恶化病例失衡而提前终止,共随机130例。
  • 第6周CDAI缓解率:210mg组3%、350mg组15%、700mg组9%、安慰剂组3%。
  • 除克罗恩病恶化外,各组不良事件总体发生率相似。

核心结论

  • 布罗达鲁单抗治疗活动性克罗恩病患者出现不成比例的克罗恩病恶化病例,且无有意义的疗效证据。
  • 除活动性克罗恩病患者克罗恩病症状恶化外,这些分析未提示布罗达鲁单抗的其他安全性风险。

研究设计与样本

  • 2期随机双盲安慰剂对照剂量探索研究,纳入中重度克罗恩病且有活动性炎症证据的患者。
  • 患者按1:1:1:1随机接受布罗达鲁单抗210mg、350mg或700mg(基线和第4周给药)或安慰剂。
  • 主要终点为第6周达到克罗恩病活动指数(CDAI)缓解(≤150)的患者比例。
  • 研究因活动治疗组克罗恩病恶化病例失衡而提前终止,终止时共随机130例。

主要发现

  • 第6周CDAI缓解率:210mg组3%、350mg组15%、700mg组9%、安慰剂组3%。
  • 第6周CDAI应答(较基线下降≥100)率:210mg组16%、350mg组27%、700mg组15%、安慰剂组13%。
  • 第6周CDAI较基线平均变化:210mg组-8.7(95.3)、350mg组-35.4(105.6)、700mg组-0.6(105.9)、安慰剂组-28.2(86.0)。
  • 除克罗恩病恶化外,各治疗组不良事件总体发生率相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究因活动治疗组克罗恩病恶化病例失衡而提前终止,终止时共随机130例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the safety and efficacy of brodalumab, a human anti-interleukin-17 receptor monoclonal antibody, in patients with moderate-to-severe Crohn's disease (CD). METHODS: Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study in patients with moderate-to-severe CD and evidence of active inflammation. Patients were randomized 1:1:1:1 to receive brodalumab (210, 350, or 700 mg at baseline and week 4) or placebo. The primary end point was proportion of patients achieving Crohn's disease activity index (CDAI) remission (≤150) at week 6. Secondary end points included proportion of patients with CDAI response (reduction from baseline of ≥100) at week 6 and change from baseline in CDAI at week 6. RESULTS: The study was terminated early based on an imbalance in worsening CD in active treatment groups. At the time of termination, 130 patients had been randomized. At week 6, remission rates were 3% (210 mg), 15% (350 mg), 9% (700 mg), and 3% (placebo) and CDAI response occurred in 16% (210 mg), 27% (350 mg), 15% (700 mg), and 13% (placebo) of patients. Mean change in CDAI at week 6 was -8.7 (95.3) (210 mg), -35.4 (105.6) (350 mg), -0.6 (105.9) (700 mg), and -28.2 (86.0) (placebo). Besides worsening of CD, overall incidences of adverse events were similar across treatment groups. CONCLUSIONS: Treatment with brodalumab resulted in a disproportionate number of cases of worsening CD in patients with active CD and no evidence of meaningful efficacy. These analyses did not suggest additional safety risks of brodalumab beyond worsening of CD symptoms in patients with active CD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Targan SR, Feagan B, Vermeire S, et al. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. Am J Gastroenterol. 2016. PMID: 27481309. doi:10.1038/ajg.2016.298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。